Director Preclinical Development
Team
Michael Albers serves as Director of Preclinical Development at FundaMental Pharma.
With more than 25 years of experience in drug development, particularly in the field of small molecules, he has successfully advanced numerous programs from early discovery through to Phase 1 clinical trials.
Throughout his career, Michael has held roles as scientist, project leader, and director of assays and screening, contributing to the development of drug candidates across diverse therapeutic areas, including metabolic disorders, autoimmune and inflammatory diseases, as well as oncology.
He has worked with leading German biotech companies such as LION Bioscience, Phenex Pharmaceuticals, WM Therapeutics, and Affimed.
Michael Albers earned a German Diploma (MSc) and a PhD from the University of Edinburgh, Scotland. He is (co-)author of more than 20 peer-reviewed scientific publications and reviews, and inventor on multiple granted and pending patents.
